The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
This Fellowship will focus on the development of novel therapeutics for cancer, and identify mechanisms for selection of treatments best suited to individual patients. It will also develop innovative strategies to identify cancer through molecular imaging techniques.
This program of work focuses on smoking related lung diseases including chronic bronchitis and emphysema, and lung cancer, as well as diseases affecting the blood vessels in the lungs. The work includes basic cell biology and human clinical trials.There is a high likelihood that new approaches to treating lung disease will emerge.
Molecular Determinants Of Progression And Treatment Response In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$467,068.00
Summary
Melanoma, a skin malignancy of pigment cells, is a major Australian health problem and is the commonest cancer in young adults. This project utilises the resources of the world’s largest melanoma treatment service and aims to develop a scientific basis for 1) improved management of individuals at high risk for melanoma progression, and 2) improved treatment of patients with early and disseminated melanoma, in an era of rapid change in the prospects of successfully treating this dangerous cancer.
Translating Molecular Pathology Into Cancer Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and technologies. Other integral aims are to identify new changes in DNA and other cancer cell markers in patients, assess the clinical utility of these as biomarkers (surrogates of cancer behaviour) and to conduct novel clinical trials with newly identified molecular targets of cancer and new therapeutics and combinations to assess their efficacy.
Chronic myeloid leukaemia was almost always fatal before the development of imatinib a decade ago, the first tyrosine kinase inhibitor (TKI) developed to treat a human cancer. There are now more potent TKIs that are effective in cases of resistance to imatinib. The challenge now is to optimise the achievement of remissions using these drugs and convert CML into a curable condition. This will be the focus of my NHMRC Practitioner Fellowship over the next 5 years.
Identification And Early Treatment Of Autoimmune Brain Disease In Children
Funder
National Health and Medical Research Council
Funding Amount
$406,491.00
Summary
Acquired brain injury affects 2% of Australians, particularly young people, and can result in permanent disability. Most acquired brain injury is not reversible, however ‘autoimmune brain disease' is due to an overactive immune system and is treatable with modulation of the immune system. By measuring antibodies in the blood, this fellowship will result in early identification and treatment of autoimmune brain disease, and improve outcomes.
Molecular Imaging As A Critical Tool In Discovery Of The Basis Of Tumour Heterogeneity And Developing Novel Therapies To Overcome Therapeutic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.
Molecular Imaging To Advance Treatment Of Dementia
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Molecular imaging using a scan technique called positron emission tomography, enables detection and measurement of specific pathological features of disease such as the amyloid plaques of Alzheimer’s disease. This project will develop this technology for other aspects of brain disorders including dementias, Parkinson’s disease, traumatic brain injury and schizophrenia and use it to assist development of therapies and improve clinical diagnosis nation wide.
Translating Advances In Molecular Oncology Into Improved Care For Patients With Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$411,327.00
Summary
The purpose of my research is to develop and integrate into routine practice better treatment paradigms for patients with blood cancers – leukaemias, lymphomas, myeloma. My research seeks to (i) bring a new class of anti-cancer targeted therapy, inhibitors of Bcl-2, into routine care; (ii) discover the genetic changes that explain why slow growing lymphoid cancers change into rapidly fatal lymphomas; and (iii) integrate new molecular tests into the management of patients with acute leukaemia.
Integration Of Basic And Translational Genitourinary Cancer Research Into Academic Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Improvements in human health can only occur when the best basic research is tested in the best clinical trials and then applied in clinical practice across the board. Practitioner Fellowships are designed to support people who bridge these areas. This Fellowship will support an integrated program of research involving laboratory studies in prostate cancer, clinical trials in prostate and other types of cancer, application to clinical practice, and high level clinical and research leadership.